The Private Market for Anti-TB Drugs in India

Topics: Tuberculosis, Tuberculosis treatment, Pharmacology Pages: 39 (10224 words) Published: September 26, 2014
Chapter for:
When People Come First: Anthropology & Social Innovation in Global Health, João Biehl & Adriana Petryna (Eds.) Durham, NC: Duke University Press.

DRAFT PAPER – PLEASE DO NOT CITE OR CIRCULATE WITHOUT
AUTHORS' PERMISSION

Stefan Ecks & Ian Harper*

"There is No Regulation, Actually":
The Private Market for Anti-TB Drugs in India

*This paper emerged from the collaborative research project Tracing Pharmaceuticals in South Asia (2006-2009) that was jointly funded by the Economic and Social Research Council and the Department for International Development (RES-167-25-0110). The project team comprised: Soumita Basu, Gitanjali Priti Bhatia, Samita Bhattarai, Petra Brhlikova, Erin Court, Abhijit Das, Stefan Ecks, Ian Harper, Patricia Jeffery, Roger Jeffery, Rachel Manners, Allyson Pollock, Santhosh M.R., Nabin Rawal, Liz Richardson, and Madhusudhan Subedi. Martin Chautari (Kathmandu) and the Centre for Health and Social Justice (New Delhi) provided resources drawn upon in writing this paper. Neither ESRC nor DFID is responsible for views advanced here. We would also like to thank Amy Davies and Reena Ricks for sharing their Edinburgh MSc dissertations on public-private mixes with us.

1

Introduction: "74%"

Ten years ago, Paul Farmer called tuberculosis the "forgotten plague" (Farmer 2000: 185). While millions of people were dying every year of TB, the disease had become invisible for people living in rich countries. TB used to be at the forefront of public interest when it was rampant in the richer industrialized countries. But thanks to better nutrition, healthier living conditions, and more effective drugs, TB "ceased to bother the wealthy" (2000: 185). Against this forgetfulness, Farmer urged anthropologists to listen to the voices of the poor and to record their stories of deprivation and discrimination. But he also said that ethnography was insufficient to grapple with the problem. A comprehensive perspective on tuberculosis "must link ethnography to political economy and ask how large-scale social forces become manifest in the morbidity of unequally positioned individuals in increasingly interconnected populations" (2000: 197). Ethnographers could touch on "structural violence," but were unable to fully analyze it with their own methods.

Since the WHO declaration of TB as a global emergency in 1993, the fight against tuberculosis has received far more attention than previously, and even pessimists would now find it difficult to call TB a "neglected" disease. Several global initiatives have emerged to bring effective anti-TB drugs to even the world's poorest regions. For example, the Global Fund to Fight AIDS, Tuberculosis and Malaria (GFATM) has distributed US$19.3 billion to 572 programs in 144 countries (Global Fund 2010) since its 2

foundation in 2002. The WHO's push to spread directly observed treatment, shortcourse (DOTS) across all countries through their national TB control programs was also of great importance. DOTS aims to detect all TB cases through sputum microscopy and to enroll all patients into a treatment regime lasting six to eight months. DOTS has had many successes, and the global number of cases per capita has been falling by about 1% per year since 2004. However, the total number of cases is still growing due to overall population growth (WHO 2009: 1).

More awareness of the limits of this approach has led to the expansion of DOTS from 2005. The "Stop TB Strategy" (WHO 2010) contains six components: 1) expand and enhance DOTS; 2) focus on the poorest people, on HIV-co-morbidity, and on multi-drug resistant TB (MDR-TB); 3) strengthen primary health care; 4) engage all care providers; 5) empower people with TB; 6) promote research into new diagnostics, drugs, and vaccines. The strategy to "engage all care providers" entails plans to involve an array of voluntary, corporate, and private providers and to extend collaborations in "PublicPrivate Mixes (PPM)" (WHO 2009:...


References: Chaganti, S.R. 2007. Pharmaceutical marketing in India. New Delhi: Excel Books.
Chaudhuri, S. 2005. The WTO and India 's pharmaceuticals industry. New Delhi: Oxford
University Press.
Das, V. & Das, R.K. 2007. How the body speaks: Illness and the lifeworld among the
urban poor
Ecks, S. 2008. Three Propositions for an evidence-based medical anthropology. Journal of
the Royal Anthropological Institute, S77-S92.
Ecks, S. 2010. Near-liberalism: Global corporate citizenship and pharmaceutical
marketing in India
Farmer, P. 2000. The consumption of the poor: Tuberculosis in the 21st century.
Global Fund for AIDS, Tuberculosis and Malaria. 2010. [About the Global Fund]
http://www.theglobalfund.org/en/about/
Hacking, I. 1995. The looping effects of human kinds. In D. Sperber, D. Premack, A.J.
Harper, I. 2005 Interconnected and interinfected: DOTS and the stabilisation of the
tuberculosis control programme in Nepal
Hayden, C. 2007. A generic solution? Pharmaceuticals and the politics of the similar in
Mexico
Rangan, S. 2008. India 's revised national tuberculosis control programme:
Looking beyond detection and cure
Kleinman, A. 1980. Patients and healers in the context of culture: An exploration of the
borderland between anthropology, medicine, and psychiatry
Latour, B. 1987. Science in action: How to follow scientists and engineers through society.
Latour, B. 1993. We have never been modern. Trans. Catherine Porter. Cambridge, MA:
Harvard University Press.
Latour, B. 2005. Reassembling the social: An introduction to actor-network-theory. Oxford:
Oxford University Press.
Lupin. 2009. Annual Report 2008-2009. Mumbai: Lupin Limited. (download at
www.lupinworld.com; last accessed 27 June 2010)
Prasad, R., Nautiyal, R.G., Mukherji, P.K., Jain, A., Singh, K., & Ahuja, R.C. 2002.
Ryan, F. 1992. Tuberculosis: The greatest story never told. Swift Publishers.
Singla, N., Sharma, P.P., Singla, R. & Jain, R.C. 1998. Survey of knowledge, attitudes and
practices for tuberculosis among general practitioners in Delhi, India.
TB Alliance. 2007. Pathway to Patients: Charting the dynamics of the global TB drug market.
Uplekar, M.W., Shepard, D.S. 1991. Treatment of tuberculosis by private general
practitioners in India
World Health Organization. 2010a. Stop TB strategy.
Continue Reading

Please join StudyMode to read the full document

You May Also Find These Documents Helpful

  • Anti Drug Essay
  • Essay on LV and MV Switchgear Market in India
  • Drugs in India Essay
  • Drugs Essay
  • Treatment of Tb Essay
  • India Market Essay
  • Essay about Anti Drug Legislation Matrix
  • Anti Aids Drug AZT Essay

Become a StudyMode Member

Sign Up - It's Free